Collegium Pharmaceutical
COLL
eBay
EBAY
Halozyme Therapeutics
HALO
SilverCrest Metals
SILV
Workday
WDAY
(FY)Sep 30, 2024 | (FY)Sep 30, 2023 | (FY)Sep 30, 2022 | (FY)Sep 30, 2021 | (FY)Sep 30, 2020 | (FY)Sep 30, 2019 | (FY)Sep 30, 2018 | (FY)Sep 30, 2017 | (FY)Sep 30, 2016 | (FY)Sep 30, 2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 10.80%42B | 33.06%37.91B | 18.48%28.49B | -6.26%24.05B | -16.12%25.65B | 2.62%30.58B | -1.44%29.8B | 18.35%30.23B | -4.17%25.55B | -2.62%26.66B |
Operating revenue | 10.80%42B | 33.06%37.91B | 18.48%28.49B | -6.26%24.05B | -16.12%25.65B | 2.62%30.58B | -1.44%29.8B | 18.35%30.23B | -4.17%25.55B | -2.62%26.66B |
Cost of revenue | 9.81%28.08B | 32.99%25.57B | 16.80%19.23B | -6.06%16.46B | -14.79%17.52B | 1.74%20.56B | -0.20%20.21B | 16.99%20.25B | -4.23%17.31B | -2.98%18.07B |
Gross profit | 12.85%13.93B | 33.20%12.34B | 22.14%9.26B | -6.69%7.58B | -18.86%8.13B | 4.47%10.02B | -3.93%9.59B | 21.21%9.98B | -4.04%8.23B | -1.84%8.58B |
Operating expense | 11.89%10.93B | 30.36%9.77B | 14.81%7.5B | -10.13%6.53B | -7.14%7.27B | 5.13%7.82B | -4.70%7.44B | 21.74%7.81B | -3.97%6.41B | -1.98%6.68B |
Selling and administrative expenses | 10.00%11M | 27.93%10M | -16.83%7.82M | 21.77%9.4M | 4.65%7.72M | -19.13%7.38M | 36.16%9.12M | 2.81%6.7M | -14.02%6.51M | -22.24%7.58M |
-General and administrative expense | 10.00%11M | 27.93%10M | -16.83%7.82M | 21.77%9.4M | 4.65%7.72M | -19.13%7.38M | 36.16%9.12M | 2.81%6.7M | -14.02%6.51M | -22.24%7.58M |
-Depreciation and amortization | 10.29%1.05B | 16.78%952M | -11.37%815.19M | -12.59%919.75M | 38.97%1.05B | 6.83%757.18M | 1.35%708.78M | 25.98%699.31M | 0.08%555.08M | -0.14%554.64M |
Other operating expenses | 11.26%6.68B | 35.16%6B | 30.96%4.44B | -11.35%3.39B | -16.77%3.82B | 7.09%4.59B | -5.56%4.29B | 20.10%4.54B | -2.69%3.78B | 2.19%3.89B |
Operating profit | 16.51%2.99B | 45.27%2.57B | 67.50%1.77B | 22.27%1.06B | -60.66%863.16M | 2.19%2.19B | -1.19%2.15B | 19.37%2.17B | -4.29%1.82B | -1.35%1.9B |
Net non-operating interest income expense | -58.29%-277M | -39.92%-175M | 17.57%-125.07M | 11.98%-151.72M | -27.48%-172.37M | 8.97%-135.21M | 2.75%-148.53M | -16.05%-152.72M | 16.50%-131.6M | -12.84%-157.6M |
Non-operating interest income | -43.40%30M | 427.35%53M | 24.75%10.05M | -10.53%8.06M | -26.74%9M | 57.24%12.29M | -2.75%7.82M | 54.22%8.04M | 14.64%5.21M | -44.01%4.55M |
Non-operating interest expense | 38.01%305M | 60.90%221M | -14.75%137.35M | -13.02%161.12M | 23.52%185.24M | -4.08%149.96M | -2.75%156.35M | 17.50%160.76M | -15.62%136.81M | 9.72%162.15M |
Total other finance cost | -71.43%2M | 413.42%7M | -66.34%-2.23M | 65.21%-1.34M | -56.98%-3.86M | ---2.46M | ---- | ---- | ---- | ---- |
Other net income (expense) | ||||||||||
Special income (charges) | -122.07%-664M | -98.34%-299M | 57.15%-150.75M | 15.07%-351.79M | -51.79%-414.21M | -232.45%-272.88M | -6,227.05%-82.08M | 103.95%1.34M | 34.25%-33.88M | -388.41%-51.52M |
-Less:Restructuring and merger&acquisition | 38.71%258M | 81.05%186M | -24.24%102.74M | 59.73%135.61M | -46.04%84.9M | 2,315.19%157.34M | 586.27%6.51M | -103.81%-1.34M | -29.65%35.18M | 926.40%50.01M |
-Less:Impairment of capital assets | 143.33%146M | 388.45%60M | -75.27%12.28M | -56.11%49.68M | --113.2M | --0 | ---- | ---- | ---- | ---- |
-Less:Other special charges | 945.83%203M | -816.40%-24M | -98.30%3.35M | 143.55%197.38M | 841.86%81.04M | -88.61%8.6M | --75.57M | ---- | -185.98%-1.3M | 106.66%1.52M |
-Write off | -25.97%57M | 137.77%77M | 204.86%32.38M | -122.86%-30.88M | 26.30%135.07M | --106.94M | ---- | ---- | ---- | ---- |
Income before tax | -3.79%2.06B | 30.27%2.14B | 163.31%1.64B | 130.63%623.01M | -85.29%270.14M | -7.45%1.84B | -5.05%1.98B | 21.42%2.09B | -2.00%1.72B | -5.47%1.76B |
Income tax | 22.29%642M | 33.56%525M | 173.60%393.08M | 48.91%143.67M | -77.64%96.48M | -13.99%431.45M | -3.75%501.62M | 25.38%521.13M | -2.73%415.66M | -4.66%427.34M |
Net income | -12.28%1.41B | 29.23%1.61B | 160.22%1.25B | 176.02%479.34M | -87.64%173.66M | -5.24%1.4B | -5.49%1.48B | 20.16%1.57B | -1.76%1.31B | -6.05%1.33B |
Net income continuous Operations | -12.28%1.41B | 29.23%1.61B | 160.22%1.25B | 176.02%479.34M | -87.64%173.66M | -5.24%1.4B | -5.49%1.48B | 20.16%1.57B | -1.76%1.31B | -5.72%1.33B |
Minority interest income | 100.00%10M | 11.94%5M | 4.47M | 0 | -73.84%2.57M | -5.66%9.83M | -22.20%10.42M | 2.81%13.4M | 7.48%13.03M | 24.41%12.12M |
Net income attributable to the parent company | -12.63%1.4B | 29.30%1.61B | 159.29%1.24B | 180.17%479.34M | -87.74%171.09M | -5.24%1.4B | -5.34%1.47B | 20.33%1.56B | -1.85%1.29B | -6.26%1.32B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -12.63%1.4B | 29.30%1.61B | 159.29%1.24B | 180.17%479.34M | -87.74%171.09M | -5.24%1.4B | -5.34%1.47B | 20.33%1.56B | -1.85%1.29B | -6.26%1.32B |
Basic earnings per share | -10.74%0.823 | 31.89%0.922 | 160.32%0.6991 | 160.95%0.2685 | -88.31%0.1029 | -5.26%0.8801 | -2.75%0.929 | 21.37%0.9552 | -4.52%0.787 | -0.41%0.8243 |
Diluted earnings per share | -10.75%0.822 | 31.75%0.921 | 160.32%0.6991 | 160.95%0.2685 | -88.29%0.1029 | -5.39%0.8789 | -2.75%0.929 | 21.57%0.9552 | -4.49%0.7857 | -0.39%0.8227 |
Dividend per share | 23.16%0.5623 | 52.26%0.4566 | 0.2999 | 0 | -29.53%0.3469 | 4.26%0.4923 | 11.76%0.4722 | -2.20%0.4225 | -1.99%0.432 | 2.37%0.4408 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |